<DOC>
	<DOCNO>NCT03088280</DOCNO>
	<brief_summary>Single-center , prospective , randomize , open-label clinical trial evaluate 1-year efficacy safety rATG 3mg/kg compare 6mg/kg low moderate immunological risk patient receive low exposure tacrolimus plus everolimus ( EVL ) steroid-free protocol .</brief_summary>
	<brief_title>Efficacy Safety Rabbit Antithymocyte Globulin 3mg/kg Kidney Transplant Patients Under Steroid-free CNI Minimization Maintenance Immunosuppressive Regimen</brief_title>
	<detailed_description />
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Primary kidney transplant recipient , adult PRA &gt; 50 % DSA &gt; 1500 MFI Retransplantation Patients plan receive mycophenolate instead everolimus Patients plan followup another center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>